您的当前位置:首页 > 行业数据 > 帕博利珠单抗、NSCLC分别是全球PD-(L)1市场产品层面、适应症层面的重中之重
图片属性
图片格式:PNG 图片大小:721KB 图片尺寸:2304*742
同报告图片
 / 4
帕博利珠单抗、NSCLC分别是全球PD-(L)1市场产品层面、适应症层面的重中之重_第1页
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
帕博利珠单抗、NSCLC分别是全球PD-(L)1市场产品层面、适应症层面的重中之重_第2页
fCDlk4HniYwgICAgICAgfCDljaDmr5QgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS18CnwgQkFJIFpFIEFOICB8IDM1JSAgfAp8IFRZVllUICAgICAgfCAyNSUgIHwKfCBBTCBSVUkgS0EgIHwgMTUlICB8CnwgS0VZVFJVREEgICB8IDEwJSAgfAp8IFRVTyBZSSAgICAgfCA1JSAgIHwKfCBIQU4gU0hJIFpIVUFORyB8IDMlICB8CnwgVEVDRU5UUklRICB8IDIlICAgfAp8IE9QRElWTyAgICAgfCAyJSAgIHwKfCBBTiBOSSBLRSAgIHwgMSUgICB8CnwgRU4gV0VJIERBICB8IDElICAgfAp8IE9USEVSUyAgICAgfCAxJSAgIHwKCui1hOaWmeadpea6kO+8mklRVklB77yM5Lit5rOw6K+B5Yi456CU56m25omA
帕博利珠单抗、NSCLC分别是全球PD-(L)1市场产品层面、适应症层面的重中之重_第3页
帕博利珠单抗、NSCLC分别是全球PD-(L)1市场产品层面、适应症层面的重中之重_第4页
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
帕博利珠单抗、NSCLC分别是全球PD-(L)1市场产品层面、适应症层面的重中之重_第5页
所属报告: 康方生物-港股公司研究报告-双特异抗体龙头国际化之路现胜利曙光-240621(37页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠